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INTRODUCTION
Pleural effusion is defined as the accumulation of fluid in
the pleural space that exceeds the physiologic amount of 10-
20 mL. Heart failure is the main cause of pleural effusion
(30-40%). In the non-cardiac effusion, pneumonia is the
most common (48%) (1), of which approximately 75% are
bacterial. Determining the etiology is greatly facilitated by
the ability to analyze the pleural fluid via thoracentesis, a
simple bedside procedure. The most practical method for
differentiating diagnosis is Light criteria, which separated
transudates from exudates by analyzing protein and lactate
dehydrogenase (LDH) levels of serum and pleural fluid (1). 
However, only a select number of diagnoses can be estab-
lished definitively by thoracentesis and results of quantita-
tive cultures are not available until 24-72 hr after the proce-
dure. Moreover, bacteriological evidence of infection may not
develop simultaneously as clinical signs of sepsis and nega-
tive results do not exclude sepsis because of poor sensitivity
by culture. Delays in the administration of adequate antimi-
crobial treatment increase the risk of mortality (2). On the
other hand, unnecessary use of antibiotics increases drug resis-
tance, side effects, and expense. Since common clinical and
laboratory measurements lack the sensitivity and specificity,
other tests are needed to identify the infectious cause of a gen-
eralized inflammatory response and to allow early diagnosis
and appropriate treatment.
Among the potentially available laboratory parameters,
procalcitonin (PCT) has recently become of interest as a pos-
sible marker of the systemic inflammatory response to infec-
tion (3). It is normally produced in the C-cells of the thy-
roid gland and is the precursor of calcitonin. A specific pro-
tease cleaves PCT to calcitonin, Katacalcin, and an N-ter-
minal residue. Normally, PCT is cleaved and none is released
into the blood stream such that levels are undetectable (<0.1
ng/mL) in healthy humans. In severe bacterial infections and
sepsis, however, intact PCT is found in blood. PCT levels
increase in response to a stimulus within 2-6 hr. A half-life
of approximately 20-24 hr is expected for PCT after a single,
acute stimulus. Unlike most cytokines, PCT is highly stable
in collected blood samples. Thus, it has been described as a
good predictor of disease severity and antibiotic efficiency (4).
PCT measurements may be helpful in differentiating bet-
ween infectious or non-infectious causes in patients present-
ing with a systemic inflammatory response syndrome, and
may differentiate between viral and bacterial infections. Abrupt
increases or high PCT values in these patients warrant a search
for infection. Numerous clinical studies have also proposed
PCT as a specific marker of bacterial infection or general in-
flammation (5-7). However, localized bacterial infections with-
out systemic manifestations, like bacterial parapneumonic
effusion (PPE) without sepsis, may cause only a small to mod-
est increase (0.3-1.5 ng/mL). Therefore, treatment, such as
antibiotics, may be necessary despite normal PCT levels (8).
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Serum and Pleural Fluid Procalcitonin in Predicting Bacterial Infection
in Patients with Parapneumonic Effusion 
This study evaluated the value of procalcitonin (PCT) levels in pleural effusion to
differentiate the etiology of parapneumonic effusion (PPE). Forty-one consecutive
PPE patients were enrolled and were divided into bacterial and non-bacterial PPE.
Blood and pleural effusion samples were collected for PCT measurement on admis-
sion and analyzed for diagnostic evaluation. PCT of pleural fluid was significantly
increased in the bacterial PPE group (0.24 ng/mL) compared to the non-bacterial
PPE group (0.09 ng/mL), but there was no significant difference for serum PCT. A
PCT concentration of pleural fluid >0.174 ng/mL (best cut-off value) was consid-
ered positive for a diagnosis of bacterial PPE (sensitivity, 80%; specificity, 76%;
AUC, 0.84). Pleural effusion PCT in the bacterial PPE is significantly different from
those of the non-bacterial PPE and control groups, so the diagnostic use of PCT
still warrants further investigation.
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If PCT was measured in body fluids other than serum, con-
flicting results have been reported. PCT values measured in
urine fluctuate over a wide range. On average, approximately
25% of the plasma concentrations can be detected in the urine
(9). But alveolar PCT does not seem to be a helpful parame-
ter in the early diagnosis of ventilator-associated pneumonia
and is not an appropriate marker for predicting mortality (10).
This study aimed to determine the usefulness and reliability
by PCT level of pleural fluid in the diagnosis of bacterial PPE.
MATERIALS AND METHODS
Subjects
Forty-one consecutive patients with PPE from the Divi-
sion of Pulmonary/Critical Care Medicine and Infectious
Disease of the Department of Internal Medicine at the St.
Martin De Porres Hospital in Chiayi from August to Decem-
ber 2006 were included and PPE was diagnosed if they had
a score >6 as assessed by clinical pneumonia infection score
(CPIS) at baseline or 72 hr (11), and if ultrasound examina-
tion showed pleural effusion. All had undergone diagnostic
thoracentesis and venipuncture, with measurement of PCT
in the pleural fluid and serum, after obtaining ethical research
approval from the hospital’s Institutional Review Board and
informed consent from the patients. Specifically, PPE was
categorized as definite bacterial infection if bacterial colonies
were identified by blood culture, effusion culture, or quan-
titative cultures from bronchoscopic broncho-alveolar lavage
fluid (BAL). The criteria for the diagnosis of non-bacterial
PPE were the negative or non-significant growth in culture
of the three kinds of specimens.
Blood and pleural effusion samples were also collected from
9 routine, non-pneumonic effusion patients who acted as
the control group. The control group (non-pneumonic) was
defined with CPIS ≤6 at baseline and 72 hr, and diagnosed
as another disease accounting for the chest radiograph abnor-
mality of pleural effusion. All had either congestive heart fail-
ure (n=8) or chronic renal failure (n=1) but not pneumonia. 
None of the 50 patients had received systemic or topical
antimicrobial therapy 3 days before the study, none had
smoked at least one cigarette per day for 1 yr, and none had
a diagnosed thyroid disease or small cell lung cancer.
Measurements
Ultrasound-guided thoracentesis was performed to obtain
pleural fluid. Blood samples were obtained by venipuncture
and specimens were collected in tubes containing ethylene-
diamine tetraacetic acid (EDTA), centrifuged at 3,000 rpm
for 10 min at 4℃, and the supernatants were stored at -20℃
for later determination of PCT if the patient was enrolled
after 72 hr. The same technologist running the all PCT assay
was blinded of the clinical information. The quantitative deter-
mination of PCT was performed with LUMI test PCT, an
immunoluminometric assay manufactured by B.R.A.H.M.S
Diagnostica GmbH, Hennigsdorf/Berlin (12). 
Samplings for blood culture were tested in BD BACTEC
lytic/10 anaerobic and standard/10 aerobic. BAL fluid was
obtained from fiberoptic bronchoscope Olympus with 200
mL warm sterile saline administrated to the involved lobe.
Samples were then plated onto dishes: Trypticase soy agar
5% SB, chocolate II agar, eosin methylene blue agar, and
Columbia colistin-nalidoxic acid agar. Bacterial colonies were
counted and identified using conventional techniques.
Statistical analysis 
Statistical analysis was carried out using SPSS version 10.0
for Windows software. Demographic data was expressed as
median with 95% confidence interval. Sensitivity and speci-
ficity were expressed in percentages. After confirming nor-
mally distributed data, demographic data was compared using
the independent t test or the chi-square test when appropri-
ate. The non-parametric Kruskal-Wallis tests or the Bonfer-
roni criteria of Mann-Whitney U tests for continuous vari-
ables were used to compare PCT level among groups. The
difference was statistical significant if Pwas <0.05. The receiv-
er-operating characteristic (ROC) curves were analyzed to
define the optimal cut-off value and used to compare diag-
nostic accuracy. Sensitivity, specificity, and area under the ROC
curve (AUC) were estimated using a standard formula. 
Results are expressed as mean (95% confidence interval).
*Independent t test and chi-square test for quantitative and categorical
variables, respectively. 
CPIS, clinical pulmonary infection score; PSI, pneumonia severity index;
COPD, chronic obstructive pulmonary disease.
Bacterial group
(n=25)
Non-bacterial
group (n=16)
P
value*
Age (yr) 62.8 66.47 0.448
(55.75-69.61) (59.29-73.65)
Gender (M/F) 17/8 13/3 0.477
CPIS 8.00 7.41 0.043
(7.55-8.45) (7.15-7.67)
PSI score 101.88 102.12 0.982
(88.02-115.74) (85.64-118.50)
Days in admission 18.40 15.24 0.306
(14.64-22.16) (9.82-20.65)
Diabetes mellitus (%) 4 (16) 8 (50) 0.041
Neoplasm (%) 1 (4) 1 (6.25) 1.000
Chronic liver disease (%) 3 (12) 0 (0) 0.260
Chronic renal disease (%) 3 (12) 1 (6.25) 0.635
Congestive heart failure (%) 2 (8) 2 (12.5) 0.379
Neurologic disease (%) 6 (24) 1 (6.25) 0.210
COPD (%) 6 (24) 4 (25) 0.733
Miscellaneous (%) 10 (40) 7 (43.75) 0.755
Table 1. Demographic and clinical data of the study patients400 Y.-C. Ko, W.-P. Wu, C.-S. Hsu, et al.
RESULTS
The study population was composed of 50 patients (35
males and 15 females) with a median age of 67 yr. Of these,
25 had bacterial PPE, 16 had non-bacterial PPE, and 9 made
up the control group.
Table 1 showed demographic and clinical data of the PPE
patients divided into two subgroups and showed the under-
lying medical disease. A significant difference occurred for
the variables of CPIS and diabetes mellitus.
The diagnosis of bacterial PPE was established in 25 cases:
8 patients had gram-negative bacilli, 13 had Gram-positive
cocci, and 4 had polymicrobial growth. Overall, pleural fluid
culture findings were positive in 9 of 25 patients, broncho-
scopic BAL quantitative culture was positive in 16 patients,
and 4 had positive blood cultures.
The median PCT levels in pleural fluid were significantly
higher in the bacterial PPE (0.24 ng/mL) than in the non-
bacterial PPE (0.09 ng/mL) and the control groups (0.08 ng/
mL, P<0.001), but no statistical difference was found in serum
concentrations among the three groups (P=0.205, Table 2).
Regarding non-bacterial PPE diagnosis, no significant dif-
ferences occurred in the non-bacterial PPE group compared
to the control group for pleural PCT (Fig. 1). Others, LDH
and glucose levels of pleural fluid also demonstrated signifi-
cant differences among the three groups, but pleural protein
level did not (Table 2).
The cut-off value of pleural fluid PCT for diagnosis of
bacterial PPE (from the ROC curve; AUC=0.84) was 0.17
ng/mL (Fig. 2). This corresponded to 80% sensitivity and
76% specificity, in contrast to 72% sensitivity and 94%
specificity with a well-known serum cut-off value (0.5 ng/
mL) for bacterial infection (Table 3) (13).
DISCUSSION
PPE occurs in approximately 10% of patients with com-
munity-acquired pneumonia (14) and most bacterial PPE
will resolve with antibiotic treatment alone. Thus, identifi-
cation of the possible etiology represents an initial challenge
to clinicians in facilitating PPE. Limitations and inaccura-
cies in clinical decision-making have motivated the devel-
Results are expressed as median (25th-75th percentiles).
*Kruskal Wallis test of non-parametric test.
PCT, procalcitonin; LDH, lactate dehydrogenase.
Bacterial 
(n=25)
Control
(n=9)
Non-bacterial
(n=16)
P
value*
Serum PCT  0.136 0.081 0.086 0.205
(ng/mL) (0.016-3.867) (0.046-0.317) (0.013-0.159)
Pleural fluid
PCT (ng/mL) 0.24 0.09 0.08 <0.001
(0.037-2.72) (0.06-0.30) (0.005-0.155)
Protein (mg/dL) 2,488 1,890 1,580 0.220
(1,625-3,850) (1,600-3,675) (1,033-1,870)
Glucose (mg/dL) 97.1 164.4 156.9 0.006
(15.3-173.2) (109.8-216.8) (86.1-204.8)
LDH (IU/L) 242.5 233.6 85.5 0.002
(157-981.25) (145.7-492.5) (65-157.3)
Table 2. Serum and pleural procalcitonin levels on hospital admis-
sion for the three groups of patients
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Fig. 1. Comparison of pleural concentrations of procalcitonin among
the bacterial parapneumonic effusion (PPE), non-bacterial PPE,
and control groups (Bonferroni criteria of Mann-Whitney U test).
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Fig. 2. Receiver-operating characteristic (ROC) curve analysis of
pleural concentrations of procalcitonin and diagnosis of bacterial
parapneumonic effusion.
AUC, area under receiver-operation characteristic curves; PCT, pro-
calcitonin.
Test Specificity Sensitivity AUC
Serum PCT >0.5 ng/mL 72% 94% 0.85
Pleural PCT >0.17 ng/mL 80% 76% 0.84
Table 3. Measurements of diagnostic accuracy of identifying
tests for bacterial parapneumonic effusionProcalcitonin in Parapneumonic Effusion 401
opment of techniques to establish the diagnosis of bacterial
PPE and guide treatment decisions to significantly reduced
antibiotic administration or avoid neglecting bacterial infec-
tions. Gram stain and cultures of tracheal secretions have
been commonly used but are non-specific and lack the sen-
sitivity for establishing the presence of bacterium partly
because of oro-pharyngeal colonization and difficulties in
obtaining definite pathogens from an inadequately expecto-
rated specimen. Several methods have been developed in an
attempt to improve their diagnostic accuracy, including C-
reactive protein (CRP) and bacterial antibody assays. CRP
levels are usually lower in viral and superficial bacterial infec-
tions than in deep bacterial infections (15) but their role in
the etiologic diagnosis of respiratory infections is not well
established and their usefulness in distinguishing between
bacterial and viral pneumonia have conflicting results (16).
Clinical analysis of antibody-coated bacteria is not sensitive
enough for the exclusion of bacterial pneumonia. Also its
routine use is limited due to the cost and unavailability in
clinical laboratory (17). Among these chemical parameters
in our study, LDH and glucose in pleural fluid showed sig-
nificant differences between the three groups, but pleural
protein level did not. We believed that the difference of glu-
cose level came from patients with empyema in bacterial
PPE group. For the LDH level, the transudative nature of
the control group might contribute the statistical difference
by Light’s criteria for pleural effusion. However, to our knowl-
edge, these parameters could not be a guideline for diagno-
sis or treatment at present, when they were used in a single.
PCT, a circulating serum calcitonin precursor, is a 116
amino-acid protein stimulated by bacterial inflammation
and produced by neuro-endocrine cells of different organs,
including the lungs (18). Thus, patients with small cell lung
cancer and thyroid disease were excluded for the neurocrine
nature in our study. To our knowledge, elevated serum lev-
els of PCT have been found in several diseases such as sepsis
syndrome, inhalation burn injury, and infectious pneumoni-
tis (19). It is important that PCT is elevated in bacterial infec-
tions but remain low in viral infections (20). It also deserved
our attention because that the measurement of PCT with
LUMI test is easy and can be completely within two hours.
We could absolutely get the information of bacterial infec-
tion much more quickly as compared with identifying bac-
teria by culture. Furthermore, its serum concentration is more
sensitive and specific than CRP, interleukin-6 (IL-6) or white
blood cell count for differentiating bacterial and viral causes
of community-acquired pneumonia (CAP) (12) and is utilized
to guide treatment decisions to significantly reduce antibi-
otic use and costs without adverse effects on outcomes (21).
However, localized bacterial infections or infections without
systemic manifestations cause only a small to modest increas-
es in PCT levels. Treatment, such as antibiotics, may there-
fore be necessary in patients with pneumonia despite normal
PCT levels. In previous studies, since pneumonia is generally
an organ related infection, PCT values are usually low even
in the presence of marked clinical symptoms or radiographic
findings (22). 
In the demographic data, a significant difference occurred
in the variables of CPIS and diabetes mellitus between the
bacterial and non-bacterial PPE group. CPIS was used to
diagnose pneumonia and was not related to PCT levels. Our
findings warrant further studies that will take into consid-
eration the association of diabetes mellitus and PCT levels.
PCT has been measured in body fluids other than serum
in only few papers and with conflicting results (9). In 2005,
Cakir et al. (23) reported that serum and pleural fluid PCT
concentrations were statistically different between tubercu-
lous and nontuberculous pleurisy groups, even though they
were not elevated up to the cut-off level of 0.5 ng/mL. This
study was to verify whether PCT levels measured in pleural
effusion could be a marker of bacterial PPE and present with
a more sensitive or specific parameter than serum levels to
identify non-septic bacterial infection and prevent the unnec-
essary use of broad-spectrum therapy. Based on the results
here, PCT measurement in pleural effusion represents a poten-
tial adjunct to the diagnosis of bacterial PPE despite the lack
of statistical difference among the three groups in terms of
serum levels. To our knowledge, BAL fluid PCT concentra-
tions remained undetectable in previous studies due to the
hypothesis that the alveolar membrane could be a strong fil-
ter to circulating cytokines (24). The low alveolar PCT release
could be the same with some local mediators, like tumor
necrosis factor α (25). Otherwise, PCT has been proposed as
an indicator of severe generalized infections or sepsis, while
localized infections or infections without systemic manifes-
tations cause only a limited increase (26). PCT induction is
consequently generally slight in isolated pneumonia due to
the organ-related nature of the infection. In our study, the
severity of PPE was not taken into consideration and pneu-
monic severity index score demonstrated a non-significant
difference between the bacterial and non-bacterial PPE groups.
Thus, we could regard the PPE as a localized infection and
our cases might not be so serious to cause sepsis. Then we
consequently found that the serum PCT levels in our study
were almost lower than the current cutoff value of 0.5 ng/mL
and it was not significantly increased in the bacterial PPE
group as compared with the non-bacterial or control group.
At the time, we believed that pleural fluid might play a role
for diagnosis in such the localized infection, like PPE.
This study has limitations. First, the gold standard for eval-
uating the diagnosis of pneumonia remains the open lung
biopsy instead of the CPIS score, although the appropriate-
ness of studying a diagnostic test only among dead patients
is debatable. Second, a lower threshold value (0.01 ng/mL)
of the quantitative determination by homogeneous immuno-
assay may be inappropriate for detecting low, meaningful
concentrations. Lastly, some bacterial pneumonia, such as
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could not be cultured easily in traditional media. On the other
hand, some culture-positive PPE patients possibly came from
contaminations.
In conclusion, this study shows that the pleural fluid PCT
levels in bacterial PPE are significantly different from those
of the non-bacterial and control groups. However, both the
serum and pleural fluid PCT levels in patients with bacteri-
al PPE are below the current cut-off level of 0.5 ng/mL. In a
patient with a pleural fluid PCT concentration of <0.17 ng/
mL, other confusing reasons of bacterial PPE can be ruled out
with a 76% probability. If pleural fluid PCT >0.17 ng/mL,
bacterial PPE can be diagnosed with an 80% probability.
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